Denis Chem Lab (BSE 537536)₹59.95+3.67%Pharmaceuticals
In the Mar 2026 quarter (standalone), Denis Chem Lab reported sales of ₹46.77 Cr, up 13.1% from Mar 2025, and net profit of ₹0.41 Cr, down 43.1% year on year. For the year to Mar 2026, sales were ₹182 Cr and net profit ₹8.02 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.52 | 45.45 | 40.07 | 39.86 | 41.27 | 47.84 | 42.85 | 41.37 | 43.27 | 46.18 | 45.50 | 46.77 |
| Expenses | 37.39 | 40.25 | 34.03 | 34.76 | 36.85 | 41.90 | 38.98 | 39.26 | 36.47 | 41.86 | 39.46 | 44.18 |
| Operating Profit | 5.04 | 5.16 | 6.01 | 5.09 | 4.36 | 5.90 | 3.84 | 2.07 | 6.80 | 4.27 | 6.05 | 2.55 |
| OPM % | 11.9% | 11.4% | 15.0% | 12.8% | 10.6% | 12.4% | 9.0% | 5.0% | 15.7% | 9.3% | 13.4% | 5.5% |
| Other Income | 0.00 | 0.51 | 0.25 | 0.58 | 0.31 | 0.57 | 0.29 | 1.16 | 0.29 | 0.64 | 0.43 | 0.53 |
| Interest | 0.08 | 0.08 | 0.12 | 0.22 | 0.11 | 0.08 | 0.06 | 0.22 | 3.57 | 0.22 | 0.21 | 0.19 |
| Depreciation | 1.60 | 1.77 | 1.85 | 1.76 | 1.64 | 1.67 | 1.85 | 1.74 | 0.20 | 1.66 | 1.84 | 1.75 |
| Profit before tax | 3.37 | 3.82 | 4.27 | 3.70 | 2.91 | 4.72 | 2.21 | 1.28 | 3.32 | 3.02 | 4.43 | 1.15 |
| Tax % | 20.3% | 33.0% | 25.2% | 26.0% | 28.8% | 25.0% | 20.7% | 44.1% | 25.4% | 27.1% | 24.7% | 64.9% |
| Net Profit | 2.69 | 2.55 | 3.21 | 2.74 | 2.09 | 3.54 | 1.77 | 0.72 | 2.49 | 2.22 | 3.33 | 0.41 |
| EPS (Rs) | 1.92 | 1.82 | 2.30 | 1.96 | 1.49 | 2.53 | 1.26 | 0.50 | 1.78 | 1.58 | 2.38 | 0.28 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 97.98 | 112 | 107 | 123 | 135 | 109 | 136 | 161 | 167 | 173 | 182 | 182 |
| Expenses | 88.99 | 97.92 | 94.85 | 110 | 120 | 98.85 | 122 | 142 | 146 | 157 | 164 | 162 |
| Operating Profit | 8.02 | 14.04 | 12.04 | 14.03 | 15.04 | 10.03 | 14.03 | 19.04 | 21.05 | 16.05 | 18.04 | 19.67 |
| OPM % | 9.1% | 12.1% | 11.1% | 11.1% | 11.1% | 9.1% | 11.1% | 12.1% | 13.1% | 9.1% | 10.1% | 10.8% |
| Other Income | 0.00 | 0.99 | 0.99 | 1.99 | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 1.99 | 1.99 | 1.89 |
| Interest | 6.99 | 5.99 | 4.99 | 2.99 | 2.99 | 1.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 4.19 |
| Depreciation | 6.02 | 7.02 | 6.02 | 6.02 | 7.03 | 6.02 | 6.03 | 8.02 | 7.03 | 7.03 | 7.02 | 5.45 |
| Profit before tax | −2.99 | 1.99 | 2.01 | 5.99 | 5.99 | 2.99 | 9.01 | 10.99 | 15.01 | 11.01 | 12.01 | 11.92 |
| Tax % | 30.0% | 37.0% | −5.0% | −7.0% | 26.0% | 27.0% | 30.0% | 28.0% | 26.0% | 27.0% | 29.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.80 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | −4.01 | 1.01 | 2.01 | 6.01 | 4.01 | 2.01 | 6.01 | 8.01 | 11.02 | 8.02 | 8.02 | 8.45 |
| EPS (Rs) | −4.15 | 0.88 | 1.53 | 4.57 | 3.02 | 1.62 | 4.50 | 5.65 | 8.03 | 5.81 | 6.05 | 6.02 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 22.0% | 0.0% | 46.0% | 33.0% | 35.1% | 31.0% | 26.0% | 41.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.97 | 8.98 | 11.97 | 13.97 | 13.96 | 13.96 | 13.97 | 13.97 | 13.96 | 13.97 | 13.97 | 13.97 |
| Reserves | 8.00 | 7.01 | 18.03 | 36.06 | 43.06 | 45.06 | 48.08 | 53.06 | 58.14 | 66.16 | 71.13 | 78.20 |
| Borrowings | 48.02 | 44.04 | 37.07 | 25.05 | 23.01 | 14.01 | 9.01 | 3.00 | 2.01 | 1.01 | 1.01 | 4.01 |
| Other Liabilities | 16.92 | 23.88 | 26.87 | 25.87 | 25.88 | 24.89 | 21.89 | 26.87 | 24.88 | 27.86 | 25.87 | 28.85 |
| Total Liabilities | 80.91 | 84.91 | 93.94 | 101 | 106 | 96.92 | 91.95 | 95.90 | 98.99 | 109 | 112 | 125 |
| Fixed Assets | 41.83 | 39.85 | 43.83 | 39.83 | 49.80 | 45.84 | 40.86 | 41.82 | 34.86 | 37.88 | 38.85 | 36.84 |
| CWIP | 0.00 | 9.99 | 1.01 | 5.01 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 39.08 | 35.07 | 49.10 | 56.11 | 55.11 | 52.08 | 51.09 | 55.08 | 62.12 | 72.12 | 73.13 | 88.19 |
| Inventories | 3.97 | 5.50 | 5.16 | 7.08 | 8.39 | 8.49 | 9.07 | 9.86 | 9.09 | 10.16 | 9.78 | 10.56 |
| Trade receivables | 25.37 | 22.69 | 31.85 | 30.80 | 35.99 | 34.99 | 32.91 | 31.83 | 31.27 | 31.65 | 30.64 | 38.63 |
| Cash & equivalents | 1.81 | 2.81 | 7.40 | 11.13 | 5.66 | 3.62 | 4.53 | 8.82 | 16.91 | 25.10 | 26.19 | 28.97 |
| Total Assets | 80.91 | 84.91 | 93.94 | 101 | 106 | 96.92 | 91.95 | 95.90 | 98.99 | 109 | 112 | 125 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 13.99 | 20.97 | 6.99 | 10.98 | 7.99 | 12.98 | 7.99 | 16.98 | 15.98 | 17.99 | 11.99 | 3.99 |
| Cash from investing activity | −27.97 | −12.99 | −0.99 | −15.99 | −1.99 | −1.99 | −0.99 | −9.99 | −11.01 | −14.99 | −7.99 | −4.99 |
| Cash from financing activity | 13.03 | −7.01 | 0.00 | 1.01 | −5.01 | −14.03 | −6.01 | −7.02 | −4.01 | −4.01 | −4.01 | 0.00 |
| Net cash flow | −0.99 | 0.99 | 4.99 | −3.99 | 0.99 | −2.99 | 0.99 | 0.00 | 0.99 | −0.99 | 0.00 | 0.00 |
| Capex | 28.44 | 12.62 | 2.17 | 8.31 | 9.54 | 2.18 | 0.00 | 0.00 | 0.00 | 6.91 | 7.60 | 4.64 |
| Free cash flow | −13.98 | 7.99 | 4.99 | 1.99 | −1.99 | 10.99 | 5.99 | 11.98 | 11.99 | 10.99 | 3.99 | −0.99 |
| CFO / OP % | 154.0% | 246.0% | 49.0% | 92.0% | 65.0% | 101.0% | 85.0% | 126.0% | 100.0% | 104.0% | 105.0% | 38.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 123 | 85 | 104 | 105 | 106 | 94 | 110 | 85 | 71 | 69 | 65 | 78 |
| Inventory days | 40 | 39 | 35 | 52 | 50 | 51 | 60 | 50 | 39 | 43 | 37 | 40 |
| Days payable | 81 | 119 | 136 | 150 | 102 | 108 | 103 | 99 | 79 | 90 | 81 | 81 |
| Cash conversion cycle | 82 | 5 | 4 | 9 | 56 | 38 | 68 | 37 | 32 | 23 | 22 | 37 |
| Working capital days | −19 | −57 | −13 | 4 | 17 | 32 | 63 | 51 | 41 | 37 | 38 | 50 |
| ROCE % | 11.0% | 5.0% | 11.9% | 9.0% | 11.0% | 11.0% | 6.0% | 14.0% | 16.0% | 19.9% | 14.0% | 14.0% |
For the Mar 2026 quarter, Denis Chem Lab reported sales of ₹46.77 Cr, up 13.1% year on year and net profit of ₹0.41 Cr, down 43.1% year on year. The operating margin was 5.5%.
Denis Chem Lab's sales for the year to Mar 2026 were ₹182 Cr; over the last twelve months they were ₹182 Cr.
Net profit for the year to Mar 2026 was ₹8.02 Cr, and ₹8.45 Cr over the last twelve months. Earnings per share over the same trailing period were ₹6.02.
Denis Chem Lab reported borrowings of ₹4.01 Cr at Mar 2026, against cash and equivalents of ₹28.97 Cr.
Cash from operations was ₹3.99 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹0.99 Cr.